← Back to Search

Antiplatelet Agent

Selatogrel for Heart Attack (SOS-AMI Trial)

Phase 3
Waitlist Available
Research Sponsored by Idorsia Pharmaceuticals Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Current dialysis.
Known liver impairment significantly affecting the hepatic function.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up total duration: up to 30 days
Awards & highlights
Pivotal Trial

Summary

This trial will test if a new drug can help people recently discharged from the hospital with type 1 heart attacks who have other risk factors for heart disease.

Who is the study for?
This trial is for patients who've had a type 1 heart attack within the last 4 weeks and have additional cardiovascular risks like diabetes, kidney disease, or prior heart attacks. They must be able to use an autoinjector and not have severe liver issues, recent strokes, known allergies to P2Y12 drugs like Selatogrel, bleeding risks or be on certain blood thinners.
What is being tested?
The study tests Selatogrel against a placebo in people who recently had a heart attack. Participants are chosen at random after leaving the hospital to receive either the actual drug or a dummy injection without knowing which one they're getting.
What are the potential side effects?
While specific side effects of Selatogrel aren't listed here, similar drugs can cause bleeding problems, bruising easily, shortness of breath and sometimes allergic reactions. The severity varies from person to person.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently on dialysis.
Select...
My liver function is significantly impaired.
Select...
I am currently on a combination of blood thinners and antiplatelet medications.
Select...
I have a history of serious bleeding or conditions that increase my risk.
Select...
I am allergic to selatogrel or similar medications.
Select...
My hemoglobin level is below 10 g/dL due to chronic anemia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~total duration: up to 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and total duration: up to 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinical status as assessed by a 6-point ordinal scale
Occurrence of Type 3 or 5 treatment-emergent bleeding events according to the Bleeding Academic Research Consortium (BARC) definition
Secondary study objectives
Occurrence of death, non-fatal acute myocardial infarction, hospitalization or unplanned emergency department visit for heart failure (Composite endpoint)

Side effects data

From 2018 Phase 2 trial • 346 Patients • NCT03384966
1%
Atrial fibrillation
1%
Non-cardiac chest pain
1%
Syncope
1%
Angina pectoris
1%
Cardiac arrest
1%
Ventricular fibrillation
1%
Oedema peripheral
1%
Dizziness
1%
Vertigo
1%
Malaise
1%
Pain in extremity
1%
Blood glucose increased
1%
Chronic obstructive pulmonary disease
1%
Fatigue
1%
Gastric haemorrhage
1%
Herpes zoster
1%
Myalgia
1%
Nasopharyngitis
1%
Oropharyngeal pain
1%
Dyspnoea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Follow-up Period - Selatogrel 8 mg
Follow-up Period - Selatogrel 16 mg
Treatment Period - Selatogrel 8 mg
Treatment Period - Selatogrel 16 mg
Treatment Period - Placebo
Follow-up Period - Placebo

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: SelatogrelExperimental Treatment1 Intervention
Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
Group II: PlaceboPlacebo Group1 Intervention
Study treatment administration may occur at any time between the randomization visit and the final study visit when the participant experiences symptoms suggestive of an acute myocardial infarction. Study treatment administration triggers protocol pre-defined assessments or visits.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Selatogrel
2020
Completed Phase 2
~400

Find a Location

Who is running the clinical trial?

Idorsia Pharmaceuticals Ltd.Lead Sponsor
121 Previous Clinical Trials
21,953 Total Patients Enrolled
Clinical TrialsStudy DirectorIdorsia Pharmaceuticals Ltd.
2,226 Previous Clinical Trials
882,378 Total Patients Enrolled

Media Library

Selatogrel (Antiplatelet Agent) Clinical Trial Eligibility Overview. Trial Name: NCT04957719 — Phase 3
Heart Attack Research Study Groups: Selatogrel, Placebo
Heart Attack Clinical Trial 2023: Selatogrel Highlights & Side Effects. Trial Name: NCT04957719 — Phase 3
Selatogrel (Antiplatelet Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04957719 — Phase 3
~2383 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top